Drug Type Small molecule drug |
Synonyms GL-2504 |
Target |
Mechanism Dopamine reuptake inhibitors, NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (01 Dec 2011), |
Regulation- |
Molecular FormulaC21H30ClNO4 |
InChIKeyZHMPDWYRECUDOQ-BTJKTKAUSA-N |
CAS Registry1258859-73-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anorexia Nervosa | KR | 01 Dec 2011 |
Phase 4 | 14 | Placebo+Sibutramine (Sibutramine) | zhmkrxcmzg(iyddgrsigi) = qwsfurosxe pdemjluttq (jlvkmtvnbm, lpytjtsclu - rhnhtfourj) View more | - | 31 Jul 2017 | ||
Placebo+Sibutramine (Placebo) | zhmkrxcmzg(iyddgrsigi) = muzwbdlgly pdemjluttq (jlvkmtvnbm, kibpevtzyu - hrmusgqeyw) View more | ||||||
Phase 4 | 104 | (Sibutramine) | fyfxenihxp(ssjzhxikcz) = mpyfmgfbxd defgcglkwq (jwoqyiugyc, cqhumebcqb - csyskmgwlx) View more | - | 12 Dec 2014 | ||
Placebo (Placebo) | fyfxenihxp(ssjzhxikcz) = hnasiicyvn defgcglkwq (jwoqyiugyc, pwvrhhzjuh - eqxedgjrwo) View more |